Vaxcyte. has filed a patent for a process to purify high-molecular weight bacterial polysaccharides and polypeptide-polysaccharide conjugates for immunogenic compositions. The claim includes a conjugate with a GAS polypeptide antigen or non-GAS carrier polypeptide and a purified cell wall polysaccharide with a molecular weight of 10-40 kDa. GlobalData’s report on Vaxcyte gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Vaxcyte, LPS antibody-based anti-bacterials was a key innovation area identified from patents. Vaxcyte's grant share as of January 2024 was 3%. Grant share is based on the ratio of number of grants to total number of patents.
Purification process for bacterial polysaccharides for immunogenic compositions
A patent application (Publication Number: US20240000926A1) describes a polypeptide-polysaccharide conjugate for inducing a protective immune response against Group A Streptococcus (GAS) bacteria. The conjugate includes a GAS polypeptide antigen or a non-GAS carrier polypeptide with a non-natural amino acid (nnAA) containing a click chemistry reactive group, along with a purified cell wall polysaccharide or peptidoglycan-bound capsular polysaccharide. The conjugate has specific molecular weight ranges and derivatization levels of the polysaccharide repeat units, enhancing its immunogenic properties.
Furthermore, the patent application details an immunogenic composition comprising specific GAS polypeptide antigens, a polypeptide-polysaccharide conjugate with a SpyAD polypeptide, and a GAS polysaccharide variant. This composition aims to induce an antibody response against GAS bacteria while avoiding an immune response against human tissue. The method of inducing a protective immune response in a subject and the process for purifying cell wall polysaccharides from bacterial cells are also disclosed, providing a comprehensive approach to developing effective vaccines against GAS infections.
To know more about GlobalData’s detailed insights on Vaxcyte, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
